SYRE - CIK 0001636282
The table below shows Spyre Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $97.19M | $64.90M | $81.66M | $48.49M | $71.58M | $45.14M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $763.95M |
| $504.60M |
| $538.83M |
| $569.77M |
| $421.08M |
| $435.74M |
| Property, plant & equipment | - | - | - | - | - | - |
| Goodwill | - | - | - | - | - | - |
| Total assets | $763.95M | $504.60M | $538.83M | $569.78M | $421.09M | $436.07M |
| Accounts payable | - | - | - | - | - | - |
| Total current liabilities | $85.16M | $46.27M | $83.06M | $70.68M | $57.54M | $22.12M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $93.14M | $49.50M | $83.06M | $87.17M | $93.70M | $61.68M |
| Retained earnings | -$1.20B | -$1.07B | -$1.05B | -$1.02B | -$916.14M | -$847.11M |
| Total equity | $670.81M | $455.10M | $455.77M | $482.61M | $327.39M | $374.38M |